James Spicer

23PUBLICATIONS
198CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersInnate immunityTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Sep 09, 2026
Ceralasertib plus durvalumab in Ras mutant and Ras wild type advanced non-small cell lung cancer: Two cohorts of the phase II platform National Lung Matrix Trial.

|Jul 23, 2026
Oncology drug development in the UK: analysis of the past 25 years and focus on the 2026 reboot of the clinical trial regulatory framework.

|Jul 14, 2026
Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer.

|May 01, 2026
Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial.

|Mar 31, 2026
Independent Testing of Published CT Models for PD-L1 Status in Non-Small Cell Lung Cancer.

Robert O'Shea, Carolyn Horst, Thubeena Manickavasagar

|Aug 06, 2025
An oral heme oxygenase inhibitor targets immunosuppressive perivascular macrophages in preclinical models of cancer.

Meriem Bahri, Taha Al-Adhami, Emre Demirel

Pageof 4

Frequent Collaborators

9 joint publications

Sophia N Karagiannis

7 joint publications

Heather J Bax

5 joint publications

Giulia Pellizzari

4 joint publications

Silvia Crescioli